Journal of Drugs in Dermatology最新文献_第10页

Keeping Cool: An Updated Review on Cold-Induced Dermatoses and Cold-Associated Injury. 保持凉爽：冷致皮肤病和冷相关损伤的最新综述。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01

Savanna I Vidal, Nikita Menta, Adam Friedman

引用次数: 0

Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors. 拉丁美洲皮肤肿瘤管理（LACOM） I：皮肤护理在肿瘤患者和幸存者中的作用。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8565

Daniel Alcalá Pérez, Ana Sofia Acosta Madiedo, Sebastian Andreani, Anneke Andriessen, Hebert Cárdenas, Marcela Moreno, Daniel Motola Kuba, Julia Riganti, José Enrique Ollague, Mario Lacouture, Alejandra Toquica

{"title":"Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors.","authors":"Daniel Alcalá Pérez, Ana Sofia Acosta Madiedo, Sebastian Andreani, Anneke Andriessen, Hebert Cárdenas, Marcela Moreno, Daniel Motola Kuba, Julia Riganti, José Enrique Ollague, Mario Lacouture, Alejandra Toquica","doi":"10.36849/JDD.8565","DOIUrl":"10.36849/JDD.8565","url":null,"abstract":"Background: Cancer-treatment-related cutaneous adverse events (cAEs) are common and may severely impact quality of life (QoL) and decrease treatment outcomes. The Latin American Cutaneous Oncology Management (LACOM) project provides clinical insights into cancer-treatment-related cAEs, offering tools for preventing and managing cAEs.Methods: LACOM I focuses on integrating education, prophylactic measures, and skincare in cancer treatment to improve treatment adherence, outcomes, and patients' and survivors' QoL.Results: The LACOM panel provides evidence and opinion-based best practice recommendations for oncology skincare programs to support all stakeholders in the Latin American healthcare setting (Argentina, Chili, Colombia, Ecuador, Panama, Peru, and Mexico) working with oncology patients throughout the entire continuum of care to achieve optimal outcomes, improving cancer patients and survivors' QoL. Oncology skincare programs comprise hygiene, moisturization, and sun protection with products that should be safe and help to minimize cAEs and improve skin conditions.Conclusions: Integrating education, general measures, and skincare programs into cancer treatment should encourage the adoption of a proactive role of skincare from the beginning of treatment and ongoing, supporting optimal outcomes and improving cancer patients' and survivors' QoL. J Drugs Dermatol. 2025;24(3):262-268. doi:10.36849/JDD.8565.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"262-268"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alopecia Universalis: Never Give Up? 普遍性脱发：永不放弃？

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8587

Victoria Jiminez, Anna Riess, Tiffany Mayo, Boni Elewski

{"title":"Alopecia Universalis: Never Give Up?","authors":"Victoria Jiminez, Anna Riess, Tiffany Mayo, Boni Elewski","doi":"10.36849/JDD.8587","DOIUrl":"10.36849/JDD.8587","url":null,"abstract":"Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medications within this class that have been FDA-approved in recent years, with data supporting treatment response over the course of a few months.Case presentation: We present the case of a 28-year-old female with alopecia universalis and a Severity of Alopecia Tool (SALT) of 100%, who failed 1 year of baricitinib therapy and was switched to ritlecitinib. She experienced regrowth of vellus hairs on the scalp and some eyebrow hair after 6 months of therapy and subsequent robust growth of terminal hair after 1 year of ritlecitinib and 2 total years of total JAKi therapy. The patient also had regrowth of the eyelashes, eyebrows, and resolution of nail pitting.Conclusion: The authors aim to report this case to highlight the success of prolonged JAKi therapy for patients with severe refractory alopecia areata and the success of JAKi therapy after failure of a prior JAKi. Dermatologists should consider longer courses of these medications and switching within the class for patients who experience poor response with initial agents. J Drugs Dermatol. 2025;24(3):316-318. doi:10.36849/JDD.8587.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"316-318"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects on the Skin Microbiome by a Moisturizer Formulated for Eczema-Prone and Sensitive Skin. 针对易患湿疹和敏感皮肤的润肤霜对皮肤微生物组的影响。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8707

Cleo Whiting, Sara Abdel Azim, Nicolas Joly-Tonetti, Nadège Lachmann, Adam Friedman

{"title":"Effects on the Skin Microbiome by a Moisturizer Formulated for Eczema-Prone and Sensitive Skin.","authors":"Cleo Whiting, Sara Abdel Azim, Nicolas Joly-Tonetti, Nadège Lachmann, Adam Friedman","doi":"10.36849/JDD.8707","DOIUrl":"10.36849/JDD.8707","url":null,"abstract":"Background: Cutaneous dysbiosis contributes to the pathophysiology of atopic dermatitis and potentially that of sensitive skin; regulation of the bacterial communities through skincare products is an emerging management strategy. Previous studies have highlighted the utility of ingredients that function as prebiotics, are anti-inflammatory, and have barrier-repairing properties to help shift species richness and composition toward more eubiotic states.Methods: In a single-site open-label study, a moisturizer containing colloidal oatmeal, Ophiopogon japonicus root extract (AD-Resyl®, SILAB, France), and a patented filaggrin protein byproduct was evaluated for its effect on the bacterial communities of eczema-prone and sensitive skin (n=12). Skin swab samples from participants' cheeks were collected before and after applying the moisturizer twice daily for 21 days. Measures of alpha diversity (richness, Shannon diversity index) and beta diversity were calculated using paired, comparative analyses of sampled bacterial loads.Results: Bacterial species richness was significantly increased in 10 participants (P<0.05) without dysbiotic shifts in overall microbial composition.Conclusion: These results support the use of a moisturizer containing anti-inflammatory and skin barrier-repairing ingredients for managing atopic dermatitis and add to our knowledge of the skin microbiome in sensitive skin. J Drugs Dermatol. 2025;24(3):275-280. doi:10.36849/JDD.8707.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"275-280"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Social Media's Impact on Hair Loss Information Dissemination: A Systematic Review. 社交媒体对脱发信息传播的影响：一项系统综述。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.7990

Raymond Ezzat, Narges Maskan Bermudez, Antonella Tosti

{"title":"Social Media's Impact on Hair Loss Information Dissemination: A Systematic Review.","authors":"Raymond Ezzat, Narges Maskan Bermudez, Antonella Tosti","doi":"10.36849/JDD.7990","DOIUrl":"10.36849/JDD.7990","url":null,"abstract":"Objective: This systematic study examines the quality of hair loss information disseminated on social media platforms, as well as its potential effects on users' decision-making, emotional states, and societal attitudes toward hair loss.Methods: A thorough search of MEDLINE and PubMed databases was conducted until May 13th, 2023 to identify research into the role of social media in disseminating hair loss knowledge.Results: The systematic review encompasses 11 studies investigating platforms such as Facebook, Twitter, Instagram, TikTok, and YouTube. We discovered significant variations in the quality of hair loss-related information on social media. The DISCERN scores ranged from 1.47 to 2.66, while the percentage of videos/posts created by dermatologists ranged from 0 to 18.9%. While certain reliable content from medical professionals was present, there was an overabundance of personal anecdotes, unproven remedies, and recommendations based on personal experiences. The potential impacts of such information are wide-ranging, potentially influencing user decision-making and societal perceptions. Misinformation and subpar content could also heighten distress and anxiety among individuals seeking hair loss solutions.Conclusion: This review highlights the need for enhanced content quality on social media platforms. It advocates for greater involvement of medical professionals, stricter adherence to evidence-based information, and the cultivation of critical thinking skills among users.J Drugs Dermatol. 2025;24(3):307-311.     doi:10.36849/JDD.7990.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"307-311"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FULL SUPPLEMENT: Exploring The Scalp Barrier and Microbiome In Diverse Dandruff Patients. 全面补充：探索头皮屏障和微生物组在不同的头皮屑患者。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.32730

E T Al

引用次数: 0

Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial. 基于人工智能的脱发个性化治疗方案：为期6个月的临床试验

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8611

Vinay Bhardwaj, Nancy Rodgers, Oded Harth, Yoram Harth

{"title":"Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial.","authors":"Vinay Bhardwaj, Nancy Rodgers, Oded Harth, Yoram Harth","doi":"10.36849/JDD.8611","DOIUrl":"10.36849/JDD.8611","url":null,"abstract":"Hair loss affects up to 50% of women and 80% of men. The high costs and wait times for professional consultations lead many to seek one-size-fits-all solutions that are frequently ineffective. This study tested an artificial intelligence (AI) model for customizing non-medicated hair loss treatments. In a 24-week trial, 38 women with self-reported hair thinning received personalized product kits based on AI analysis of scalp images and questionnaires. Treatments included various combinations of topical serums, shampoos, oral supplements, and marine collagen peptides. Of the 27 participants who completed the study, significant improvements were observed in hair growth, coverage, and thickness (P<0.001 for all). Hair shedding decreased by 37.3% at 12 weeks and 32.4% at 24 weeks. Scalp transepidermal water loss was reduced by 61.5% at 12 weeks and 69% at 24 weeks. Scanning electron microscopy showed improved hair texture. Participants reported overall hair improvement (88.9%), better scalp health (85.2%), and less hair brittleness (92.6%) (P<0.001 for all). No adverse events were reported. The AI-driven platform effectively delivered personalized hair loss treatments, suggesting a data-driven, customized, and accessible self-served alternative for hair loss management. J Drugs Dermatol. 2025;24(3):233-238. doi:10.36849/JDD.8611.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"233-238"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Acute Hematomas and Methods to Mitigate Risk. 急性血肿的处理和降低风险的方法。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8453

Vixey Silva, Cassandra Johnson, Lisa Fronek, Richard Miller

引用次数: 0

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares. Spesolimab治疗广泛性脓疱性银屑病。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8322

Sabine L Abukhadra, Shirley P Parraga, Steven R Feldman

{"title":"Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares.","authors":"Sabine L Abukhadra, Shirley P Parraga, Steven R Feldman","doi":"10.36849/JDD.8322","DOIUrl":"10.36849/JDD.8322","url":null,"abstract":"Background: Generalized pustular psoriasis (GPP) is a rare, life-threatening neutrophilic skin condition characterized by widespread sterile eruptions. Treatment approaches vary due to a lack of standardized guidelines. Interleukin-36 signaling is involved in GPP activation and disease progression. An interleukin-36 receptor monoclonal antibody, spesolimab, is a new treatment option for GPP flares. The Effisayil 1 clinical trial investigated the efficacy and safety of spesolimab, a remarkable task due to the unpredictable nature of GPP flares coupled with intrinsic trial challenges.Methods: We searched PubMed using the terms: generalized pustular psoriasis, spesolimab, and Effisayil 1.Clinicaltrials: gov was used to identify clinical trial data including efficacy, safety, and tolerability.Results: In Effisayil 1, a phase II study, 53 patients with a GPP flare were enrolled: 35 patients were randomized to spesolimab and 18 to placebo. At baseline, 46% of the patients in the spesolimab group and 39% of the patients in the placebo group had a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 3; 37% and 33% of patients in each group, respectively, had a pustulation subscore 4. At the end of week 1, 19 of the patients in the spesolimab group, (54.3%) had a pustulation subscore of 0 compared to 1 patient in the placebo group (5.6%) (-49%, P<0.001).Conclusions: The Effisayil 1 trial faced many difficulties affecting trial completion, but the results of this study provided encouraging results. Spesolimab was effective in treating GPP flares after just one week. Patient demographics and baseline characteristics did not affect the efficacy or safety profile of spesolimab. J Drugs Dermatol. 2025;24(3):242-245. doi:10.36849/JDD.8322.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"242-245"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Efficacy of Intralesional Steroid Injections vs Cryotherapy for the Treatment of Alopecia Areata. 病灶内类固醇注射与冷冻治疗斑秃的疗效比较。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8499

Seemal Akram, Isabella J Tan, Rohan R Shah, Zainab Tariq, Hassan Javaid, Babar Rao

{"title":"Comparative Efficacy of Intralesional Steroid Injections vs Cryotherapy for the Treatment of Alopecia Areata.","authors":"Seemal Akram, Isabella J Tan, Rohan R Shah, Zainab Tariq, Hassan Javaid, Babar Rao","doi":"10.36849/JDD.8499","DOIUrl":"10.36849/JDD.8499","url":null,"abstract":"Introduction: The precise etiology of alopecia areata (AA) remains unclear. Various treatments, including corticosteroids, minoxidil, immunotherapy, and phototherapy, have shown varying efficacy. Injectable corticosteroids, despite being invasive, are the first-line treatment, while topical steroids are also commonly used.Objective: To compare the efficacy of intralesional steroid (triamcinolone acetate) versus cryotherapy for the treatment of alopecia areata over a 6-month period in the Department of Dermatology at the Pakistan Atomic Energy Commission General Hospital.Methods: The study included 118 patients (aged 15 to 50 years, both genders) with a single patch of alopecia areata on the scalp. Exclusion criteria included active secondary infections, cold intolerance, multiple patches, iatrogenic or primary immunosuppression, pregnancy, or breastfeeding. Patients were randomly assigned to two groups: Group A received intralesional steroid injections, and Group B underwent cryotherapy with liquid nitrogen. Treatment efficacy was then evaluated.Results: The mean age was 27.78 +/- 4.68 years in Group A and 26.63 +/- 4.91 years in Group B. Most patients (95, 80.51%) were aged 15 to 30 years. Males predominated with 86 (72.27%) participants, resulting in a male-to-female ratio of 2.6:1. The mean duration of alopecia areata was similar in Group A (8.51 +/- 3.94 months) and Group B (8.39 +/- 3.13 months). Group A (intralesional corticosteroids) had a significantly higher efficacy rate, with 49 patients (83.05%) responding positively, compared to 30 patients (50.85%) in Group B (cryotherapy) (P=0.0001), as shown in Table 1.Conclusion: The study concluded that the efficacy of intralesional steroids may be superior to cryotherapy for the treatment of alopecia areata. J Drugs Dermatol. 2025;24(3):294-297. doi:10.36849/JDD.8499.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"294-297"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0